医学
心房颤动
内科学
拜瑞妥
阿哌沙班
华法林
终末期肾病
心脏病学
置信区间
冲程(发动机)
达比加群
危险系数
疾病
机械工程
工程类
作者
Hafez Mohammad Ammar Abdullah,Waqas Ullah,Munnam S Jafar,Martin van Zyl,Rehan Saeed,Mahboob Alam,M. Chadi Alraies,David L. Fischman
标识
DOI:10.1016/j.carrev.2020.09.041
摘要
Abstract Background The use of warfarin in patients with atrial fibrillation (AF) and end-stage renal disease (ESRD) has been implicated with efficacy and safety concerns. Evidence on the role of direct oral anticoagulants (DOACs) in this population is limited. Methods Electronic databases were searched and articles comparing the safety and efficacy of warfarin with apixaban or rivaroxaban were identified. Pooled hazard ratios (HR) were computed using a random-effects model. Results A total of eight articles consisting of 30,806 patients; (rivaroxaban 2196, apixaban 2745 and warfarin 25,865) were identified. The pooled HR for major bleeding events favored apixaban over warfarin (0.53, 95% confidence interval (CI) 0.33–0.84, p = 0.008). Apixaban was similar to warfarin in terms of clinically relevant non-major bleeding (HR 1.08, 95% CI 0.64–1.84, p = 0.77) and stroke events (HR 1.09, 95% CI 0.85, 1.39, p = 0.99). There was no significant difference in the risk of major bleeding events (HR 0.95, 95% CI 0.50–1.81, p = 0.88) and stroke between rivaroxaban (HR 1.39, 95% CI, 0.59–3.29, p = 0.09) and warfarin. The combined results of major bleeding in the apixaban group were not affected by the sensitivity analysis. Conclusions Apixaban may have a lower risk of major bleeding and comparable risk of stroke when compared with warfarin in AF patients with ESRD.
科研通智能强力驱动
Strongly Powered by AbleSci AI